Subscribe To
MDGL / Why Top 1% Biotech Madrigal Pharmaceuticals Just Surged Closer To A Breakout
MDGL News
By Zacks Investment Research
October 2, 2023
Madrigal (MDGL) to Raise Capital Via Public Offering of $500M
Madrigal (MDGL) is raising funds through a public offering of 1.25 million shares of its common stock to use in commercial activities in the preparati more_horizontal
By The Motley Fool
September 27, 2023
Wall Street Thinks Madrigal Pharmaceuticals Could Climb 93%. Here's Why It Could Happen Soon.
Analysts have high hopes for Madrigal Pharmaceuticals over the coming year. Its drug resmetirom seems effective for a liver disease, non-alcoholic ste more_horizontal
By Zacks Investment Research
September 14, 2023
Madrigal (MDGL) Gains on NDA for NASH Therapy Acceptance by FDA
Madrigal (MDGL) gains as new drug application for resmeritom to treat nonalcoholic steatohepatitis gets accepted by the FDA in the United States. more_horizontal
By Market Watch
September 11, 2023
Madrigal Pharmaceuticals shares fall after new CEO named
Shares of Madrigal Pharmaceuticals Inc. MDGL, +2.91% fell more than 7% premarket on Monday after the company appointed Bill Sibold, a former Sanofi SN more_horizontal
By Seeking Alpha
August 20, 2023
Madrigal's Resmetirom Nears Commercialization Despite Market Concerns
Madrigal Pharmaceuticals is developing resmetirom, a drug for non-alcoholic steatohepatitis and fatty liver disease, with promising trial results. Mad more_horizontal
By Market Watch
June 30, 2023
Madrigal Pharmaceuticals' stock up 5% as company starts rolling submission for FDA approval of NASH treatment
Madrigal Pharmaceuticals Inc.'s stock MDGL, +5.00% rose 5% Friday after the company said it has started a rolling submission of a New Drug Application more_horizontal
By Seeking Alpha
May 30, 2023
Madrigal: Setting The Pace In The NASH Market (Rating Upgrade)
Madrigal Pharmaceuticals' drug, resmetirom, for non-alcoholic fatty liver diseases, received FDA's Breakthrough Therapy designation. The company is no more_horizontal
By The Motley Fool
May 24, 2023
Why Madrigal Pharmaceuticals Stock Is Marching Higher Today
The shares are continuing a yearlong winning streak today. This latest uptick appears to be the result of two tailwinds. more_horizontal